Kristine Ashcraft, B.S., MBA is a molecular biologist by training and is CEO and founder of YouScript. She has worked in the precision medicine space since 2000 and was recently named one of the 25 leading voices in precision medicine. Kristine has authored multiple publications on the clinical and economic benefits of pharmacogenomic testing including one lauded as one of the most influential publications at an AMIA meeting. She has been interviewed by numerous media outlets including the New York Times, the Wall Street Journal, and NBC Nightly News and has spoken at SXSW, ASHG, and numerous precision medicine Conferences. She is committed to being a catalyst in the adoption of precision medicine.

Dawn Barry is the President and Co-Founder of public benefit corporation, LunaPBC, which launched, LunaDNA, in December 2018 following SEC-qualification. LunaDNA is a community-owned health data sharing platform where individuals are included in the value created through its data for ownership shares model.  Prior to LunaDNA, Dawn served as the Vice President of Applied Genomics at Illumina, Inc.  Dawn joined Illumina in 2005 as their first Market Development Specialist and grew to hold leadership roles in business units, sales, and marketing for the Company. Dawn was named San Diego Business Journal’s 2017 Business Woman of the Year, was a speaker at TEDxSanDiego 2016, and is a Board Chair of the Alzheimer’s Association San Diego/Imperial Chapter. She holds a BS in Biology from the University of Vermont and a MBA from the University of Connecticut School of Business.

Chris is an accomplished software executive who has a track record for successfully applying technology to create and transform businesses across industries including retail, healthcare IT and molecular diagnostics. Ms. Cournoyer has a broad range of strategic, technological, operational, financial and management experience in Software and Healthcare IT, with companies from $5m to $200b in annual revenue. Most recently, Chris served as the Chairperson for the Board of Directors for N-of-One, a privately held venture backed company in molecular diagnostics/genomics decision support. Chris has experience serving on the Finance, Audit, and Compensation Committees, and has chaired a Technology Committee for two of the boards and has also served on a nonprofit board as a member of the Emerson Hospital Board of Trustees. Leading teams with a focus on developing strategies for operational excellence, global partnerships, product direction and mergers and acquisitions, Chris has also successfully led the acquisition and integration of more than 15 companies. Ms. Cournoyer has strong functional knowledge of Information Technology, Healthcare, and Fulfillment Operations and has operated successfully in both large and small companies, publicly traded companies as well as privately venture backed companies. Chris has moved successfully across industries with software as the common thread across these companies. She has held executive general management roles in two publicly traded companies; was President and CEO in two venture backed companies and Vice President in two multi-billion companies.  Ms. Cournoyer has raised venture capital, planned, acquired and integrated over 15 acquisitions, and successfully sold two companies. Chris is presently a Strategic Advisor to Qiagen.

Nicholas (Nic) Dracopoli, Ph.D. is currently a consultant to the biopharma and diagnostics . Prior to starting his consultancy, Nic was Senior Vice President of Translation Science at Personal Genome Diagnostics (PGDx) after eighteen years working in oncology drug development at Bristol Myers-Squibb (BMS) and Janssen Research & Development. In these roles, he was responsible for building two new translational science teams whose work contributed to the approval of six new oncology drugs for BMS and Janssen. Prior to joining the pharmaceutical industry, he spent five years in the biotechnology industry at Sequana Therapeutics. Nic obtained his bachelor’s degree and doctorate from the University of London and completed post-doctoral fellowships at the Memorial Sloan-Kettering Cancer Center in New York City and the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts. Subsequently, he served as an Assistant Director at the Whitehead/MIT Genome Center and as a Section Chief at the National Center for Human Genome Research at the National Institutes of Health, Bethesda, Maryland. Nic has authored more than 70 scientific publications and has extensive experience in the fields of genomics, molecular biology and cancer research.

David Houlding is the Principal Healthcare Lead on the Microsoft Azure Industry Experiences Team. David has more than 24 years of experience in healthcare spanning provider, payer, pharmaceutical, and life sciences segments worldwide, and has deep experience and expertise in blockchain, cloud computing, privacy, security, compliance, and AI / ML. David currently serves as Chair of the HIMSS Blockchain in Healthcare Task Force, a group of ~100 leaders from across healthcare worldwide, collaborating to advance blockchain in healthcare. David also currently serves as an advisor to both the British Blockchain Association and Lifeboat Foundation. David has led the successful creation and deployment of a wide range of solutions to help reduce the cost of healthcare, improve patient outcomes, experiences, and engagement. Prior to joining Microsoft in 2018 David served for over 10 years at Intel Health & Life Sciences where he was the Director of Healthcare Privacy & Security, responsible for enabling healthcare organizations worldwide to achieve compliance with regulations and data protection laws, and implement effective privacy and security programs. In his current role at Microsoft, David works with key partners and industry influencers to enable healthcare organizations make use of cloud computing and related technologies to reduce healthcare costs, and enable new transformative healthcare use cases to improve patient outcomes, leveraging strategic technologies such as such as AI / ML, blockchain, IoMT (Internet of Medical Things), and others. David has a proven track record for innovation with 5 patents granted by the USPTO. David currently holds the CISSP (Certified Information Systems Security Professional), and CIPP (Certified Information Privacy Professional) credentials, and has a Master of Applied Science in Data Compression and Digital Signal Processing from Simon Fraser University, Canada.

Tara joined Slone Partners in 2004, bringing to the company over a decade of healthcare experience. Her successful sales career with industry leaders such as VERSYSS, American Medical Laboratories, and Quest Diagnostics covered a wide variety of healthcare segments, including information technology, medical records, and the diagnostic and laboratory testing industry.

Prior to healthcare, Tara recruited executive and management talent in the banking and finance sector. Tara’s executive abilities and business acumen have been instrumental in building Slone Partners into the successful and growing company it is today. Tara drives business development strategies, creating strong partnerships with new clients and strengthening relationships with existing clients. She is a tremendous resource for clients and prospects alike.

Through her partnership with Springboard Enterprises, she is an advisor to Blumio, a startup company focused on building sensors and systems to improve health and wellness, as well as a frequent panelist and speaker at industry conferences and a participant in select industry committees; activities that provide continuing opportunities to expand Slone Partners’ knowledge and expertise in the industries we serve.

Tara graduated cum laude from Boston College, receiving a Bachelor of Science with a concentration in Human Resources Management.

Ms. Stutts is the Chief Diversity, Inclusion & Health Equity Officer for Stanford Health Care.  In addition to a proven track record as a diversity, inclusion and health equity champion, Mary is an accomplished leader who thrives on living life to the fullest, never backing away from a challenge and not hesitating to embrace the new and unexplored. Mary’s energy and zest for maintaining a transformative mindset and helping others achieve life goals is contagious – making her a sought-after advisor, speaker, advocate and board member. She has provided global leadership in biotechnology, healthcare, technology and media industries at Fortune 200 companies including Genentech, Bayer, Bristol Myers Squibb, UnitedHealth Group and Comcast NBCUniversal as well as Kaiser Permanente. Her book, The Missing Mentor, Women Advising Women on Power, Progress & Priorities provides insight and guidance on career advancement with or without a mentor.  Her book and her career development workshops on the dynamics of women and men in leadership led to her receiving the Business Council for Peace 2019 Lifetime Impact Award for advancing the careers of women.

Mary is on the Board of the Global Women’s Funding Network – the largest philanthropic network in the world devoted to women and girls.  Ms. Stutts sits on Professional Advisory Boards for The NBA Wives Association, WorldWideWomen and Wellist.  Growing up as a foster child from the age of 5 and her passion for supporting, nurturing and developing girls, aspiring professionals and entrepreneurs led Stutts to found The Excellent Life Center (TCEL), a 501c3 organization. A graduate in Communications Management at the University of Louisiana, Mary earned a Master’s degree in Health Administration at the University of Southern California. Mary is also a graduate of the Executive Program on Strategy and Organization at the Stanford University Graduate School of Business.

John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of the Department of Biostatistics at the Harvard TH Chan School of Public Health and Professor of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute. John’s PhD was in Theoretical Physics, in 1992 he received a fellowship from the National Institutes of Health to work on the Human Genome Project, which led him from the Salk Institute to Stanford University to The Institute for Genomic Research (TIGR) before moving to Harvard in 2005. John’s research uses massive data from DNA sequencing and other assays to model functional networks in human cells. By comparing networks between groups of individuals, he has found new drug targets, explored chemotherapy resistance, and investigated differences between the sexes. He has made pioneering discoveries about how the genetic variants work together to determine our traits. John has published more than 280 papers; his work has been cited more than 65,000 times. He has received numerous awards for his work, including recognition in 2013 as a White House Open Science Champion of Change. He is also the co-founder of Genospace, a precision medicine software company that was purchased by the Hospital Corporation of America in 2017.